Does Blue Cross Blue Shield Cover Farxiga?

What Is Farxiga and Why Does Formulary Placement Matter?

Farxiga is the brand name for dapagliflozin, an SGLT2 inhibitor approved by the FDA for three distinct indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD) in adults. The FDA granted approval for the heart failure indication in May 2020 and for CKD in April 2021, making Farxiga one of the few drugs with broad cardio-renal-metabolic coverage in a single tablet. [1]

Formulary placement determines how much you pay. A Tier 2 "preferred brand" placement may mean a $40, $60 copay, while a Tier 4 "non-preferred brand" slot can push your cost to $150, $350 per month before your deductible is met. Because BCBS operates as a federation of 34 independent regional companies, no single national formulary exists. Your out-of-pocket cost for the exact same drug can differ dramatically between a BCBS of Illinois plan and a BCBS of North Carolina plan. [2]

How SGLT2 Inhibitors Are Classified on BCBS Formularies

SGLT2 inhibitors as a class have gained formulary traction since large cardiovascular outcome trials demonstrated mortality benefit. The DECLARE-TIMI 58 trial (N=17,160) showed dapagliflozin reduced the composite of hospitalization for heart failure or cardiovascular death by 17% versus placebo (hazard ratio 0.83, 95% CI 0.73 to 0.95, P<0.005). [3] Results like those pushed major payers, including many BCBS affiliates, to classify Farxiga as a preferred agent in the heart failure and CKD categories on some formularies.

The American Diabetes Association 2024 Standards of Care explicitly recommend SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease, CKD, or heart failure regardless of baseline HbA1c. [4] That guideline language gives prescribers a strong clinical anchor for prior authorization letters when BCBS requests medical justification.

Generic Availability and Its Effect on Coverage

As of mid-2024, no FDA-approved generic dapagliflozin exists in the United States. The earliest Farxiga patents expire between 2025 and 2028. Without a generic alternative on formulary, BCBS plans have no low-cost substitute to push members toward, which means the brand drug must be covered or the plan must accept the cost of covering a therapeutic alternative such as empagliflozin (Jardiance) or canagliflozin (Invokana) instead. [5]

Does BCBS Specifically Cover Farxiga? Checking the Formulary

The most reliable answer comes from checking the specific plan's formulary directly. BCBS plans publish searchable drug lists on their member portals and on publicly available plan documents. Three steps give you a definitive answer in under ten minutes.

Step 1: Locate Your Plan's Formulary

Log in to your BCBS member portal (or visit your regional BCBS website without logging in) and manage to "Drug List," "Formulary," or "Prescription Drug Coverage." Enter "dapagliflozin" or "Farxiga" in the search field. The result shows tier level, any quantity limits, and whether step therapy or prior authorization applies.

Step 2: Identify Tier Placement

BCBS commercial formularies typically run four to six tiers. Farxiga appears most commonly at:

• Tier 2 (preferred brand): copay roughly $40, $70 per 30-day supply after deductible
• Tier 3 (non-preferred brand): copay roughly $80, $120 per 30-day supply
• Tier 4 (specialty or non-preferred): copay roughly $150, $350+, sometimes coinsurance-based

A 2023 analysis of Medicare Part D formularies found SGLT2 inhibitors appeared on 96% of plans, but nearly 40% placed them at Tier 3 or higher. [6] Commercial BCBS plans show similar variation.

Step 3: Check for Utilization Management Requirements

Prior authorization (PA) and step therapy are the two most common utilization management tools applied to Farxiga on BCBS plans. Step therapy typically requires a trial of metformin alone, then metformin plus a sulfonylurea or a generic DPP-4 inhibitor such as sitagliptin (Januvia), before Farxiga is approved. For the heart failure indication, step therapy to a diabetes drug often does not apply because the patient may not have diabetes at all. [7]

Prior Authorization for Farxiga on BCBS Plans

Prior authorization is required on most BCBS commercial and Medicare Advantage plans for Farxiga. The PA request must come from the prescribing physician and typically must document one of the following:

• A confirmed diagnosis of type 2 diabetes with HbA1c at or above a plan-specified threshold (commonly 7.5% or 8.0%)
• Documented intolerance or contraindication to metformin and at least one other first-line agent
• A confirmed diagnosis of HFrEF with ejection fraction <40% per echocardiography
• A confirmed CKD diagnosis with eGFR 25 to 75 mL/min/1.73m² per the FDA label [8]

The DAPA-HF trial (N=4,744) reported a 26% relative reduction in worsening heart failure or cardiovascular death with dapagliflozin 10 mg versus placebo (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001). [9] Citing this trial by name in a PA letter strengthens the medical necessity argument substantially.

What Happens If the PA Is Denied?

A first-level denial triggers your right to an internal appeal. Federal law under the Affordable Care Act requires all non-grandfathered health plans to process urgent appeals within 72 hours and standard appeals within 30 days. If the internal appeal fails, you have the right to an independent external review. [10]

The external review success rate for specialty drugs is meaningful. A 2021 report from the Kaiser Family Foundation found that enrollees won approximately 45% of external appeals across all drug types. [11] That figure underscores why filing the appeal with complete clinical documentation, including published trial data and the treating physician's letter, is worth the effort.

Writing an Effective PA Letter

A PA letter that cites specific endpoints performs better than a generic medical necessity statement. The HealthRX clinical team recommends this structure for Farxiga PA letters submitted to BCBS:

1. Patient diagnosis with ICD-10 code (E11.x for type 2 diabetes, I50.20 for unspecified HFrEF, N18.x for CKD stage)
2. Relevant laboratory values: most recent HbA1c, eGFR, BNP or NT-proBNP if applicable
3. Prior medications tried, doses, and reasons for discontinuation or inadequate response
4. Clinical trial citation supporting the specific indication (DAPA-HF for HFrEF, DAPA-CKD for CKD, DECLARE-TIMI 58 for type 2 diabetes with cardiovascular risk)
5. Guideline reference (ADA 2024 Standards, KDIGO 2022 CKD guidelines) [12]

BCBS Medicare Advantage Coverage for Farxiga

Medicare Part D plans, including those administered by BCBS Medicare Advantage, are required to cover at least two drugs in every therapeutic category. SGLT2 inhibitors fall under the antidiabetic category, meaning at least two members of this class must appear on every Part D formulary. Farxiga may or may not be one of the two selected drugs on your specific BCBS Medicare Advantage plan. [13]

Part D Low-Income Subsidy (Extra Help)

Enrollees who qualify for the Part D Low-Income Subsidy pay a maximum of $4.50 per generic and $11.20 per brand drug in 2024, regardless of formulary tier. If Farxiga is on the formulary, LIS-eligible patients pay those capped amounts. [14] The Social Security Administration estimates approximately 13 million Medicare Part D enrollees qualify for full or partial LIS benefits.

Coverage Gap Considerations

Under the redesigned Medicare Part D structure effective January 2025, out-of-pocket spending is capped at $2,000 per year. In 2024 (the last year of the old structure), a coverage gap still applied, though manufacturer discounts reduced effective cost. Patients on BCBS Medicare Advantage plans with Farxiga at Tier 3 or above should ask their pharmacist to calculate total annual cost projections before the plan year begins. [15]

Cost Without Prior Authorization Approval or Without Insurance

If BCBS denies coverage and all appeals are exhausted, or if a patient is uninsured, Farxiga's list price runs approximately $627 per 30-day supply of the 10 mg dose as of 2024. That figure is not the price most patients pay, because multiple programs reduce that cost substantially. [16]

AstraZeneca's Farxiga Savings Card

AstraZeneca offers a manufacturer savings card for commercially insured patients who do not have government insurance (Medicare, Medicaid, TRICARE). Eligible patients may pay as little as $0 per month. Income and eligibility criteria apply. The program is managed at farxiga.com and requires annual re-enrollment. [16]

AstraZeneca Patient Assistance Program (AZ&Me)

For patients with household income at or below 600% of the federal poverty level who lack adequate prescription coverage, AstraZeneca's AZ&Me program may provide Farxiga at no cost. A prescriber must complete the enrollment form, and approval typically takes two to four weeks. [16]

GoodRx and Other Discount Programs

GoodRx coupons for dapagliflozin currently show prices ranging from approximately $420 to $580 per 30-day supply at major pharmacies, depending on location. While this is lower than list price, it remains substantially higher than the copay under most BCBS plans with coverage. These discount programs cannot be combined with insurance; the patient must choose one or the other at the point of sale.

Farxiga for Heart Failure: A Coverage Category Worth Noting Separately

The heart failure indication changes the coverage calculation significantly. Patients prescribed Farxiga for HFrEF who do not have diabetes are not subject to diabetes-specific step therapy requirements. BCBS plans that apply diabetes step therapy (metformin first, then add-on agents) may inadvertently deny Farxiga for a non-diabetic HFrEF patient using the wrong clinical criteria.

The DAPA-HF trial enrolled patients with and without type 2 diabetes, and the benefit was consistent across both groups (interaction P<0.001 for heterogeneity absent). [9] The FDA label explicitly does not restrict the heart failure indication to patients with type 2 diabetes. [1] If a BCBS plan denies Farxiga for HFrEF citing failure to try diabetes drugs, that denial is clinically incorrect and should be appealed with the FDA label and DAPA-HF publication attached.

KDIGO Guidelines and CKD Coverage

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in CKD gives SGLT2 inhibitors a Grade 1A recommendation (the highest level) for patients with type 2 diabetes and CKD. [12] For CKD without diabetes, KDIGO 2024 updates extend this recommendation based on the DAPA-CKD trial (N=4,304), which showed dapagliflozin reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes by 39% versus placebo (hazard ratio 0.61, 95% CI 0.51 to 0.72, P<0.001). [17]

BCBS plans that cover Farxiga for CKD typically require documentation of eGFR and urine albumin-to-creatinine ratio (UACR) values meeting the trial and label criteria. Current FDA labeling specifies Farxiga is indicated to reduce the risk of eGFR decline, ESKD, cardiovascular death, or hospitalization for heart failure in adults with CKD at risk of progression. [1]

Therapeutic Alternatives BCBS May Prefer

When Farxiga is not on a BCBS formulary or is placed at a high tier, the plan may prefer an alternative SGLT2 inhibitor. Empagliflozin (Jardiance) and canagliflozin (Invokana) are the two most common alternatives.

Empagliflozin (Jardiance)

The EMPA-REG OUTCOME trial (N=7,020) demonstrated empagliflozin reduced cardiovascular death by 38% versus placebo in patients with type 2 diabetes and established cardiovascular disease. [18] Jardiance carries FDA approval for type 2 diabetes, HFrEF, heart failure with preserved ejection fraction (HFpEF), and CKD. If your BCBS plan places Jardiance at a lower tier than Farxiga, your prescriber may be willing to switch, provided the clinical profiles match.

Canagliflozin (Invokana)

Invokana was the first SGLT2 inhibitor approved by the FDA (March 2013) and carries indications for type 2 diabetes and CKD. The CREDENCE trial (N=4,401) showed canagliflozin reduced the primary composite kidney outcome by 30% versus placebo in patients with type 2 diabetes and CKD (hazard ratio 0.70, 95% CI 0.59 to 0.82, P<0.001). [19] Canagliflozin does carry a boxed warning for lower-limb amputation risk that dapagliflozin does not share, a factor that may influence prescriber and patient preference even if the plan favors Invokana on cost grounds.

When Switching Is Not Clinically Appropriate

Switching from Farxiga to a plan-preferred alternative is not always appropriate. If a patient has already achieved stable glycemic control, tolerates Farxiga well, and has been on it for several months, the prescriber may document medical necessity for continuity of therapy rather than step therapy to a new agent. BCBS plans generally accept continuity-of-care arguments when the treating physician provides a letter explaining why switching poses clinical risk. [20]

Step-by-Step Action Plan If Your BCBS Plan Denies Farxiga

Denial does not mean the end of access. Follow this sequence:

1. Request the specific denial reason in writing from BCBS within two business days of the verbal or written denial.
2. Ask your prescriber's office to submit a PA or a PA appeal immediately, attaching the relevant clinical trial data and guideline references listed above.
3. Request an expedited appeal (72-hour resolution) if you have an urgent medical need, such as recently diagnosed HFrEF or rapidly declining eGFR.
4. If the internal appeal fails, file for external independent review. Your denial letter must include instructions for doing so under federal law. [10]
5. Contact AstraZeneca's patient support line (1-800-236-9933) to enroll in the savings card or AZ&Me program to bridge access during the appeal process.
6. Ask your pharmacy about a 30-day emergency supply if your state's urgent supply law applies. Sixteen states have laws requiring insurers to provide emergency drug supplies during appeals. [20]

How to Verify Current Coverage Before Your Prescription Is Sent

Coverage can change at formulary update cycles, which typically occur on January 1, April 1, or July 1 each year. Checking coverage the day before your prescriber sends the prescription avoids a surprise at the pharmacy counter. Call the member services number on the back of your BCBS card and ask specifically: "Is dapagliflozin (Farxiga) 10 mg on my formulary, what tier, and does it require prior authorization?" Document the date, time, and representative name for your records. The FDA's Orange Book confirms current patent status and generic availability if you want to check whether a generic has entered the market since this article was reviewed. [5]